Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 11/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 10/20 | 0.41 |
| ▸ | SIRT3 | Q9NTG7 | 6/20 | 0.41 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.40 |
| ▸ | NPY4R | P50391 | 3/20 | 0.39 |
| ▸ | NPY1R | P25929 | 2/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.39 |
| ▸ | NPY2R | P49146 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | FAP | Q12884 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18823292 | 0.93 | SIRT2 (0.41) | SIRT2SIRT1SIRT3SIRT5NPY4R | |
| SCHEMBL18823291 | 0.93 | SIRT2 (0.41) | SIRT2SIRT1SIRT3SIRT5NPY4R | |
| SCHEMBL21230049 | 0.92 | SIRT2 (0.43) | SIRT2SIRT1SIRT3SIRT5NPY4R | |
| SCHEMBL25830938 | 0.92 | SIRT2 (0.42) | SIRT2SIRT1SIRT3SIRT5NPY4R | |
| SCHEMBL23330252 | 0.92 | SIRT2 (0.40) | SIRT2SIRT1SIRT3SIRT5NPY4R | |
| SCHEMBL23106472 | 0.92 | SIRT2 (0.40) | SIRT2SIRT1SIRT3SIRT5NPY4R | |
| SCHEMBL26319897 | 0.92 | SIRT2 (0.40) | SIRT2SIRT1SIRT3SIRT5NPY4R | |
| SCHEMBL22138818 | 0.92 | SIRT2 (0.41) | SIRT2SIRT1SIRT3SIRT5NPY4R | |
| SCHEMBL20841069 | 0.92 | SIRT2 (0.41) | SIRT2SIRT1SIRT3SIRT5NPY4R | |
| SCHEMBL18911016 | 0.92 | SIRT2 (0.41) | SIRT2SIRT1SIRT3SIRT5NPY4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11364303-B2 | Cysteine engineered antibody drug conjugates | PFIZER INC. (US) | 2022-06-21 | — | — | US | disclosed |
| US-20200377615-A1 | SITE SPECIFIC HER2 ANTIBODY DRUG CONJUGATES | PFIZER INC. (US) | 2020-12-03 | — | — | US | disclosed |
| US-10689458-B2 | Site specific HER2 antibody drug conjugates | PFIZER INC. (US) | 2020-06-23 | — | — | US | disclosed |
| US-20200069764-A1 | ANTIBODIES AND ANTIBODY FRAGMENTS FOR SITE-SPECIFIC CONJUGATION | PFIZER INC. (US) | 2020-03-05 | — | — | US | disclosed |
| US-20190099499-A1 | CYSTEINE ENGINEERED ANTIBODY DRUG CONJUGATES | PFIZER (US) | 2019-04-04 | — | — | US | disclosed |
| US-20170216452-A1 | ANTIBODIES AND ANTIBODY FRAGMENTS FOR SITE-SPECIFIC CONJUGATION | PFIZER INC. | 2017-08-03 | — | — | US | disclosed |
| US-20170151341-A1 | SITE SPECIFIC HER2 ANTIBODY DRUG CONJUGATES | PFIZER INC. (US) | 2017-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10689458-B2 | Site specific HER2 antibody drug conjugates | ERBB2, ERBB3, EGFR | SIRT2 3786/4885SIRT1 4620/4885SIRT3 4517/4885 |
| US-11364303-B2 | Cysteine engineered antibody drug conjugates | LNPEP, CTH, DNPEP | SIRT2 3938/4885SIRT1 4548/4885SIRT3 3538/4885 |
| US-20190099499-A1 | CYSTEINE ENGINEERED ANTIBODY DRUG CONJUGATES | LNPEP, CTH, DNPEP | SIRT2 3938/4885SIRT1 4548/4885SIRT3 3538/4885 |
| US-20170151341-A1 | SITE SPECIFIC HER2 ANTIBODY DRUG CONJUGATES | ERBB2, ERBB3, EGFR | SIRT2 3786/4885SIRT1 4620/4885SIRT3 4517/4885 |
| US-20170216452-A1 | ANTIBODIES AND ANTIBODY FRAGMENTS FOR SITE-SPECIFIC CONJUGATION | DNPEP, PA2G4, CD2BP2 | SIRT2 4564/4885SIRT1 4831/4885SIRT3 3858/4885 |
| US-20200377615-A1 | SITE SPECIFIC HER2 ANTIBODY DRUG CONJUGATES | ERBB2, ERBB3, EGFR | SIRT2 3786/4885SIRT1 4620/4885SIRT3 4517/4885 |
| US-20200069764-A1 | ANTIBODIES AND ANTIBODY FRAGMENTS FOR SITE-SPECIFIC CONJUGATION | DNPEP, PA2G4, CD2BP2 | SIRT2 4564/4885SIRT1 4831/4885SIRT3 3858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.